# Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

> **NCT03634982** · PHASE1 · UNKNOWN · sponsor: **Revolution Medicines, Inc.** · enrollment: 133 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RMC-4630

## Key facts

- **NCT ID:** NCT03634982
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-28
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2022-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634982, "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03634982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*